Podcasts about tirzepatide

In this episode, we take a closer look at tirzepatide, a type 2 diabetes medication also used to help with weight loss. Postmenopause weight gain can be a normal part of aging, and there are some questions about whether medications like tirzepatide could be useful and safe for postmenopausal women. Host Aaron Lohr talks with Maria Daniela Hurtado Andrade, MD, PhD, assistant professor of medicine at Mayo Clinic Florida, and Regina Castaneda, MD, a research fellow at Mayo Clinic College of Medicine & Science. They presented an abstract at ENDO 2025 titled, “One-Year Real-World Weight Loss Outcomes with Tirzepatide in Postmenopausal Women With and Without Hormone Therapy.” Show notes are available at https://www.endocrine.org/podcast/enp105 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

GET EXCLUSIVE OTP SAVINGS! www.OTPLinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

#bodybuilding #TRT #Muscle #Contestprep #bodybuildingpodcastULTIMATE GUIDE TO ROIDS #1 BOOK ON TRUTH IN THE HISTORY OF BODYBUILDING Link -⁠ ⁠⁠⁠⁠⁠https://bodybuilderinthailand.com/ultimate-guide-to-roids/⁠⁠⁠⁠⁠⁠Daily Text Msg Training 99/month and 1 Hour Phone Call Consult 59 Send Email to inquire about personal training to steroidspodcast@gmail.comBodybuilder in Thailand on Instagram: ⁠⁠⁠⁠⁠https://www.instagram.com/bodybuilderinthailand/⁠⁠⁠⁠My Other Podcast: Grab the Bull Podcast:⁠⁠⁠https://youtu.be/X6SzfCrN4NY?si=Ho2T9WIVxLjXo_AE⁠0:00 Preference for Test Propionate - Combining testosterone propionate and enanthate6:56 1st Cycle Lifting for 4 years natural with gyno from puberty11:41 Dbol Gets a Bunch of Shit Thrown at It14:55 Family Guy using tirzepatide and TRT testosterone. Looking for a good first cycle. Effects of Gear while dieting.19:42 Daily Superdrol as a First Cycle, but not trying to be Huge. Scared of Needles. 28:47 Adding Masteron to get a Big Libido 34:15 Enclomiphene - HCG - Nolvadex for Testosterone Boosting43:13 Testosterone Sustanon and Primo cycle - Sustanon Explained45:25 Old school bodybuilders had better skin49:50 Retatrutide Results - GLP1 Agonists Semaglutide Tirzepatide and Retatrutide ComparedThis Podcast is for entertainment and conversational purposes only. Serious Injury and Death can occur from utilizing chemical performance enhancement. This author does not support the use of illegal performance enhancing drugs. If any substances mentioned in this video are illegal in your country do not use them. The purpose of this podcast is not to glorify the use of PED's but to bring to light the reality of what athletes are doing privately. Consult a doctor before beginning any exercise or supplement routine. Do not take anything mentioned in this video as advice. It is simply conversation, not advice.

Today we're talking about peptides being researched for addiction. We'll unpack the science behind the incretin system, how those pathways tie into reward and substance use, and focus in on the newest triple‐agonist retatrutide. We'll also look at early evidence for alcohol, tobacco and other substance-use disorders when using certain peptide therapies. If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ What are GLP-1, GIP and the “dual/triple” agonists? First, let's review some biology to ground the discussion. GLP-1 (glucagon‐like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin hormones. Incretins are gut hormones that help with digestion and blood sugar control. They're released by the gut in response to food.  GLP-1 raises insulin levels after you eat to help lower blood sugar, slows gastric emptying, and reduces appetite. It also reduces how much glucagon your body makes. This helps to lower your blood sugar. Medications like semaglutide and dulaglutide work by mimicking GLP-1 and are often referred to as “GLP-1 agonists”. GIP has somewhat overlapping but distinct roles from GLP-1. It too, influences insulin secretion, but it also helps with fat metabolism.  In a nut shell, GIP helps fat cells respond more efficiently to insulin so they release stored fat to be used as energy when your body needs it. This process helps your metabolism shift from just storing energy to burning fat for fuel. Medications like tirzepatide work by mimicking both GLP-1 and GIP and are often referred to as “dual” agonists.  When GIP and GLP-1 are activated together — like in tirzepatide — they work as a team: GLP-1 helps control appetite and slow down digestion. GIP boosts how your body handles insulin and energy. Together, they help reduce hunger, improve metabolism, and burn fat more efficiently. Now here's where it gets a bit tricky.  A newer medication that's still in development, retatrutide, works on three hormone pathways: GLP-1, GIP, and glucagon receptors. It's called a “triple agonist”, and even though it activates the glucagon receptor, it doesn't cause high blood sugar like you might expect. It's about balance. In type 2 diabetes and obesity, the body's hormone signals are out of balance. Retatrutide gently activates the glucagon receptor, but at the same time it strongly activates GLP-1 and GIP receptors — which still help control blood sugar and increase insulin. So blood sugar stays stable or even improves overall. Glucagon doesn't just affect blood sugar — it also increases metabolism and helps the body burn fat and calories. By slightly stimulating glucagon receptors, retatrutide can boost energy use and promote fat loss without causing big spikes in blood sugar. As a result, you get the blood sugar control of GLP-1 and GIP, plus the fat-burning benefits of glucagon activation — leading to even greater weight loss and metabolic improvement.  Right now, retatrutide is in phase 3 clinical trials, which are the final stage of testing before approval. These studies are expected to finish in early 2026, and if results look good, the FDA could approve retatrutide as early as 2027.  Addiction Why is this relevant for addiction? Because the gut-brain axis, reward circuitry, and the pathways that regulate “wanting/consuming” food overlap with those involved in substance use.  Appetite, reward, and craving may share neural substrates (dopamine, GABA, mesolimbic system) and so a drug that reduces drive to eat might also modulate drive to drink, smoke or use other substances. The link between GLP-1/related drugs and substance use disorders  Let's now dive into what the research says about GLP-1 receptor agonists (and related medications) in the context of alcohol, tobacco, and other substances. Let's start with what we know from animal research. In pre-clinical studies, scientists have found that GLP-1 receptor agonists seem to change how animals respond to addictive substances. A systematic review showed that in rodents, treatment with GLP-1 drugs reduced the behavioral effects of alcohol, nicotine, amphetamine, and cocaine. For example, one GLP-1 drug called exendin-4 reduced alcohol-related behaviors in rodents. And even more recently, a study in both male and female rats showed that giving semaglutide, tirzepatide, or even retatrutide, reduced alcohol discrimination, meaning the rats didn't experience the same “feeling” from alcohol as before. This means that the “interoceptive stimulus effects” or the internal sensations — how alcohol feels inside the body, changed. This is really important because this is what often drives people to drink or relapse. So, if these medications can blunt those internal cues, it suggests they might disrupt the rewarding effects of alcohol that help maintain addiction. When we shift to human studies, things get even more interesting. A systemic review found that out of five studies looking at GLP-1 receptor agonists in people with substance use disorders — mostly alcohol and nicotine — three showed real reductions in substance use, while two did not. In one large observational study of over 150 adults with obesity who drank alcohol, those who were taking semaglutide or tirzepatide for at least 30 days reported fewer drinks, fewer binge episodes, and lower overall intake compared to people not on those drugs. A phase 2 clinical trial of once-weekly semaglutide in adults with alcohol use disorder showed similar results — lower alcohol craving and some reductions in drinking behavior. There's also data from a massive registry-based study showing that people with alcohol or opioid use disorder who were prescribed GLP-1 or GIP drugs had 50% lower rates of alcohol intoxication and a 40% lower rate of opioid overdose. Still, experts are cautious — meta-analyses and reviews consistently note that the evidence, while promising, is still early and we don't yet have large, long-term randomized controlled trials. What's Going On? So, what's actually happening inside the brain and body that could explain these changes in craving and reward? How can medications originally made for diabetes and/or weight loss end up helping with addiction?” Mechanistically, GLP-1 drugs may affect the brain's reward system — especially dopamine signaling in areas like the nucleus accumbens — and reduce the “wanting” of reward substances like food or alcohol. They might also calm stress responses and make relapse cues less powerful. And there are probably some physical effects too — things like slower digestion and increased fullness, which might make it harder to physically consume large amounts of alcohol or even smoke as much. But again, many of these findings come from animal models, which don't always perfectly reflect human addiction. Most of the focus so far has been on alcohol, though there's also some early evidence that GLP-1 drugs might influence nicotine use. For substances like opioids or cocaine, the data is thinner and more mixed. Bottom line — at this stage, GLP-1 receptor agonists, and maybe even GIP/GLP-1 dual agonists, represent a really promising new direction for treating addiction — but it's still early days. We also don't yet have human addiction studies on retatrutide, pre-clinical data in rats show that, like semaglutide and tirzepatide, it too, reduces alcohol discrimination. In practical terms, if you're treating patients with obesity or diabetes who also struggle with alcohol or nicotine use, choosing a GLP-1 or dual agonist might offer an unexpected bonus — helping with cravings. It also gives us a new way to talk with patients about how metabolism, reward, and craving are all interconnected. But — and this is important — the data are still limited. Most studies are small, short, and often focus on people with obesity or metabolic disease rather than pure addiction. So, for now, it's an adjunctive idea, not a replacement for established therapies. We'll need larger randomized trials in people with substance use disorders to really understand who benefits, what doses work, and how long the effects last. Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend, please share this episode! Until next time, be well, and as always, have a happy, healthy week.

✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog WHAT YOU WILL LEARN: How to SCULPT YOUR MUSCLES AND TIGHTEN YOUR SKIN after weight loss! How to decrease VISCERAL FAT A new way to IMPROVE MUSCLE MASS by 30% for strength and beauty in 4 weeks DECREASE SUBCUTANEOUS FAT by 25% in 4 weekly treatments INCREASE MUSCLE DEFINITION with Emsculpt Neo A way to REHABILITATE AFTER SURGERY PRE-TREAT BEFORE SURGERY: Improve your post op joint surgery condition by increasing muscle around the joint HOW TO RECOVER Quickly AFTER CHILDBIRTH A Way to IMPROVE CORE AND PELVIC FLOOR STRENGTH How EM-Sculpt-Neo works Most of you know me as the expert in Bioidentical Hormone Pellet Replacement, but I am also expert in Skin and body care.  If my patients have problems that your PCP has not been able to solve.  I will refer you for new therapies, cutting edge treatments that work to treat your problem. The most common problem that my patients complain of is loss of muscle mass and changes in body fat that make them look old.  I found a treatment that is not a laser, but the Emsculpt Neo uses safe and effective magnetic energy plus RF treatment to reduce fat and build muscle in a 30-minute painless treatment. Today I am going to talk about a painless treatment that we offer at my medical spa, BioBalance® Skin that has just been approved by the FDA for rehab after joint surgery.  The magnetic energy (HIFEM) combined with RF energy increases muscle size and strength by 30%, dissolve fat by 25%, as well as tightens skin with the same treatment! EM Sculpt Neo is a 30-minute treatment that uses magnetic energy to make your muscles contract and is equal to thousands of crunches for 30 minutes. The RF portion breaks down subcutaneous fat in the same area.  There is no work on your part, you just lie there, and your muscles respond to the magnetic pull by increasing in size and strength.  Four sessions one week apart is the ideal number of treatments, and they come a in a package of four treatments to one area. The areas that most of us want to build muscle and lose fat in are our abs, upper arms, thighs, calves, love handles, and hips. If you need to do more than one area at a treatment you can do up to three areas, each for 30 minutes. If you have had joint surgery and need to increase your strength around that joint, EMSculpt Neo is very effective, after your doctor releases you to exercise. One of the big concerns with the new weight loss medications is that people often lose muscle as they lose weight.  This is especially common after age 40, in those people who are not on testosterone pellets. EMSculpt Neo adds a tool that can preserve or even increase muscle mass and decrease fat where you want to lose it. EMSculpt Neo for fat loss and muscle building (not for rehabilitation) should be saved for those weight loss patients who lose enough weight to achieve a BMI under 30. For the best results, we suggest a high protein low carb diet, protein, low carb diet, to give your body the building blocks for muscle tissue. We also will suggest supplements for nutrition and to abstain from alcohol to get the best results. Healthy fat loss takes combination of EMSCULPT NEO, Weight Loss Medication, activity, Low carb high protein diet.  We advise our patients over BMI of 30 to get started on weight loss first and continue diet medications while you are receiving EM-Sculpt Neo treatments. How do you lose weight without losing muscle? The Best Combination for the best results while you are losing weight on medication: EMSCULPT NEO to the areas you want to remove fat from Semaglutide or Tirzepatide medication to treat obesity for weight loss Testosterone Pellets if you are a woman over 40, and man over 50. Regular exercise like walking High protein diet Supplements to improve your ability to make muscle Who should do this EMSCULPT treatment? People who are working out but cannot do sit ups because of back injury Those folks who want fast muscle mass increase in specific areas Anyone who is on a weight loss program who is losing muscle and fat, or who has saggy skin in areas where they lost weight Patients anticipating a joint surgery Patients healing from joint surgery after PT Patients who cannot lift weights because of injury Those people who lift weights but cannot develop definition People with a Beer Belly with a lot of visceral fat Some people may not be able to enjoy this sculpting, muscle building method: We will do a free consultation before you sign up for a package of EMSculpt Neo and some patients will not get optimal results if they have any of the factors below: BMI greater than 30 Metal implants anywhere that are not titanium. Titanium is not magnetic, so it is ok to have a treatment if you have a titanium joint implant. No Rods or pins. Any pacemaker implant, pain pump under your skin, nerve stimulator or you are in the first 6 weeks post-surgery for any muscle area in the area. If you have a large abdominal hernia that was not repaired, then abdominal treatment is not advisable. You can still have other areas treated. If you have unrepaired joint damage, you can still have this treatment but let us know so we can slowly work the energy up around that joint. Those people who have a pannus, an apron of skin that hangs down below the vulva, or penis will not get enough relief from this procedure. These patients will need an abdominoplasty. This surgery is done by a plastic surgeon who removes excess skin and fat and repairs the muscles and fascia. You should not waste your money if you continue to drink alcohol while undergoing this treatment. Alcohol is a toxin and will prevent the growth of muscle and loss of body fat. Don't waste your money if you are not going to follow a low carb high protein diet during and after our treatment.  How does EMSCULPT Work? EMSCULPT combines HIFEM (High Intensity Focused Electromagnetic technology) and RF (Radio Frequency). HIFEM uses magnetic energy to contract muscles in a particular area at intensities that are not achievable with routine weightlifting. Fat tissue in the treated area is also reduced by increasing metabolic activity.  This results in Body Contouring. HIFEM is approved by the FDA for Body contouring, muscle stimulation, growth and to rehabilitate patients with injuries or after surgery. The second treatment that occurs at the same time as HIFEM is RF, Radio Frequency treatment. RF is a low frequency electromagnetic wave that heats up fat in 4 minutes to stimulate collagen and elastin to tighten skin. All this happens in 30 minutes with minimal discomfort.  4 treatments, one a month, is all that is needed to increase muscle 25% and to decrease fat by 30%, and to visibly improve skin tone. Answers to questions about this procedure: What should my diet consist of to optimize my treatment? To gain muscle you must eat your weight in pounds equivalent to grams of protein every day. E.g. If you weigh 200 lbs. and you want to gain muscle, you should eat 200 grams of protein a day. What foods should I eat to optimize my treatment? The best most concentrated protein is found in animal products-eggs, milk products, fish, chicken and red meat. What supplements will help support my treatment? You may want to supplement your diet with our BioBalance Magnesium combination twice a day, Probiotics, Creatine or Arginine and Ornithine combination. You should also take a methyl B12 and Methyl Folate while you are sculpting your body. Why can't I eat a lot of carbs and drink alcohol during or after the treatment? If you eat a high carb diet, your fat loss portion of Em-Sculpt will be limited, because whatever carb you eat over-stimulates insulin, which increases insulin resistance, and increases fat deposition. Whatever is eaten goes directly to fat again and replaces what you just lost. When can I start EMSculpt after joint surgery? After PT is completed or your surgeon releases you for exercise. Can I lift weights while I am being treated? Yes, but we advise not to lift weights the day before, the day of or the day after your EMSCULPT treatment. What does hydration have to be optimal for the treatment to work effectively? The human body is almost all water, and hydration is needed for muscle contraction. Muscles don't contract optimally when you are dehydrated. We put you on a body composition machine to both document your muscle mass and fat mass, as well as tell if you are hydrated adequately. Now that you know how EMSculpt Neo can change your body composition and build muscle, I hope you are comfortable enough to let us help you get the body you have always wanted. BioBalance Skin phone for an appointment:

Girl, I am so over these creepy AI “fitness” ads. Filters are bad enough but now we have actual robots preaching toxic diet culture BS! It's wild how far we've come from Photoshop and filters — now we're literally being sold body image standards that don't even exist.In this episode, I'm venting (because seriously, what is happening?!) but also unpacking what this means for those of us healing our relationship with our bodies. Because if you're already struggling to feel good in your skin, seeing these fake “fitfluencers” can seriously mess with your head.We'll talk about: 

In today's episode, I'm diving into everything you need to know about Zepbound (tirzepatide) — the newest obesity medication now available in Canada. I'll explain how this dual GIP/GLP-1 agonist works, how it's different from semaglutide (Ozempic/Wegovy), and who it may be helpful for.We'll talk about expected weight loss results, side effects, cost, and access, as well as one really important topic: how to protect your muscle and bone health while on these medications. Rapid weight loss can come with downsides — and I'll share what you can do to make sure your journey is sustainable and healthy.In this episode, I cover: → How tirzepatide works and what makes it unique → Expected weight loss and blood sugar improvements → Common side effects and safety considerations → Tirzepatide vs. semaglutide — what's the difference? → Cost, access, and insurance coverage in Canada → Why protein and strength training are essential during weight lossAs always, this podcast is for educational purposes only and not a substitute for personalized medical advice. Please talk to your doctor before making any changes to your treatment plan.Come connect with me on Instagram @sashahighmd, and don't forget to subscribe so you never miss a Monday episode! Other episodes: 108. All About Wegovy97. All About Mounjaro53. All About Ozempic145. Which one is better, Ozempic, Wegovy or Mounjaro?

In this episode of the Heart to Heart podcast, Dr. Mike Hart sits down with Dr. Ted Naiman, a family medicine physician from Seattle with a passion for diet and exercise. They discuss the importance of family physicians in healthcare, Dr. Naiman's personal fitness transformation focusing on a high-protein, low-carb diet, and the significance of satiety over counting calories. Dr. Naiman shares his views on effective exercise routines, optimal macronutrient ratios, and the advantages of front-loading protein. They also delve into insulin resistance, the use of fasting triglycerides as a marker, and the potential of GLP-1 medications for weight loss and insulin sensitivity. This comprehensive discussion provides actionable insights into improving metabolic health and body composition. Dr. Ted Naiman is a family physician, author, and leading voice in evidence-based nutrition and metabolic health. With over two decades of experience in primary care, Dr. Naiman has dedicated his career to helping people understand the science of body composition, satiety, and sustainable weight management. Learn more at tednaiman.com  and on LinkedIn.   Links: The P:E Diet — by Dr. Ted Naiman Fairlife Milk (ultra-filtered milk)   Show Notes: 00:00 Welcome back to the Hart2Heart Podcast with Dr. Mike Hart 00:30 Dr. Ted Naiman's background 01:30 Transformation journey 02:00 Diet and exercise philosophy 03:00 Calorie counting debate 05:30 Macro ratios and protein focus 09:30 Daily meal timing and strategy 13:27 “Front-load your protein. If you start your day with donuts, you'll eat more all day. If you start with protein, you'll automatically eat less.” 20:30 Sources of protein 25:00 Carbohydrate choices 29:00 Fat sources and supplementation 34:00 Understanding insulin resistance 37:30 Understanding insulin sensitivity and resistance 39:00 Indicators of insulin resistance: triglycerides and HDL 43:30 The role of fasting insulin and glucose 50:30 Training recommendations: cardio vs. weights 52:30 Effective resistance training strategies 59:30 Visceral fat: causes and reduction strategies 01:05:30 The role of GLP-1 in weight management 01:14:30 Conclusion and final thoughts   — The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to  cutting through the noise and uncovering the most effective strategies for optimizing health,  longevity, and peak performance. This podcast dives deep into evidence-based approaches to  hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise  protocols, leveraging sunlight light, and de-prescribing pharmaceuticals—using medications only when absolutely necessary.   Beyond health science, we tackle the intersection of public health and politics, exposing how  Policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being.   Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen).   If you're ready to take control of your health and performance, this is the podcast for you. We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect on social with Dr. Mike Hart: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart  

On today's episode we discuss the latest hot topic in the fitness industry - weight loss drug, Retatrutide. What are the benefits? Are there potential side effects? What does this mean for bikini competitors in prep, dieting hard for a show? Follow us on IG @preplifepodcast @glamgirlbikini @amyehinger @leemarie183 Watch on YouTube: Glam Girl Bikini   Join the team: https://www.glamgirlbi...   1st Phorm Supplements we use: https://1stphorm.com/?... Key references • Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med / related publications (phase-2 reports). • Sanyal AJ, et al. Retatrutide and liver fat/liver outcomes. Nature Medicine 2024. • Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP). N Engl J Med 2021. • Jastreboff AM, et al. Tirzepatide once weekly for obesity (SURMOUNT) and related reports. PubMed/NEJM/SURMOUNT analyses. • Conceição-Furber E, et al. Is glucagon receptor activation the thermogenic solution? Frontiers in Endocrinology, review of GCGR and energy expenditure mechanisms. • Frampton J, et al. The acute effect of glucagon on components of energy expenditure. Int J Obes / Nature Metabolism meta-

Recorded live at Leverage Fitness, so please excuse the background noise.                        Hear what we have to say about: Longevity - Lifespan vs Healthspan Taking a look inside - why getting more extensive bloodwork is vital Weight Loss simplified - calories in vs calories out Medications, Prescriptions and Dietary Aids - deciding which might be best for you Nutrtion - do you have to eat healthy to be healthy? Supplements - which are the most important to consider? Sleep - how does it affect weight, energy and recovery? Taking control when feeling overwhelmed  Gym myths     APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

In this episode of The Jordan Syatt Podcast I speak with the incredible Dr. Danielle Belardo (IG: @daniellebelardomd) about:- The Best Diet for Heart Health- The Truth About LDL Cholesterol- How to Lower Your Blood Pressure- Tirzepatide and GLP-1's for Weight Loss- Menopause Misinformation- How Much Muscle Do You Actually Need for Health?- The Most Important Health Habits for Longevity- And more...I hope you enjoy this episode and, if you do, please leave a review on iTunes or Spotify (huge thank you to everyone who has written one so far).Finally, if you've been thinking about joining The Inner Circle but haven't yet... we have hundreds of home and bodyweight workouts for you and you can get them all here: https://www.sfinnercircle.com/

I'm back from Disney and my brain feels like… pizza.

Dr. Jerry Haas, director of our weight management program, is back with an update on the Signature Skinny Shot. After nearly two years, he and patient coordinator Lauren have fine-tuned the program with monthly check-ins, dose adjustments, and ongoing support.Dr. Haas explains how GLP-1 medications work and clears up TikTok myths with real medical data. He shares the benefits he's seen in our patients so far, from better energy and healthier blood sugar levels to being able to enjoy exercise again.He also talks about what happens once you start hitting your goals, like how to protect your muscle mass, when to shift to a maintenance dose, and what it looks like to eventually come off the medication while maintaining a healthy lifestyle.This isn't a quick fix or a magic wand, but with the right guidance, it's a powerful tool to help you feel healthier, stronger, and more in control of your weight than ever before. Find out the perks of getting your weight loss meds through a plastic surgery center instead of your primary care doctor.LinksLearn more about the Signature Skinny Shot prescription weight loss programsGet to know San Diego skinny shot director Dr. Gerald HaasLearn from the talented plastic surgeons inside La Jolla Cosmetic Surgery Centre, the 12x winner of the San Diego's Best Union-Tribune Readers Poll, global winner of the 2020 MyFaceMyBody Best Cosmetic/Plastic Surgery Practice, and the 2025 winner of Best Cosmetic Surgery Group in San Diego Magazine's Best of San Diego Awards.Join hostess Monique Ramsey as she takes you inside LJCSC, where dreams become real. Featuring the unique expertise of San Diego's most loved plastic surgeons, this podcast covers the latest trends in aesthetic surgery, including breast augmentation, breast implant removal, tummy tuck, mommy makeover, labiaplasty, facelifts and rhinoplasty.La Jolla Cosmetic Surgery Centre is located just off the I-5 San Diego Freeway at 9850 Genesee Ave, Suite 130 in the Ximed building on the Scripps Memorial Hospital campus.To learn more, go to LJCSC.com or follow the team on Instagram @LJCSCWatch the LJCSC Dream Team on YouTube @LaJollaCosmeticSurgeryCentreThe La Jolla Cosmetic Surgery Podcast is a production of The Axis: theaxis.io Theme music: Busy People, SOOP

Diabetes is a condition in which the body cannot regulate blood sugar properly. There are different types of diabetes, each with unique causes and treatment needs. Type 1 diabetes usually occurs in children or young people when the pancreas stops producing insulin completely, making lifelong insulin injections necessary. Type 2 diabetes, more common in adults but increasingly seen in children, occurs when insulin is produced but does not work effectively due to insulin resistance. It may initially be controlled through diet, exercise, and tablets, but many patients eventually require insulin. Gestational diabetes typically develops during pregnancy and often disappears after delivery, yet both the mother and child remain at higher risk of developing diabetes later. Secondary diabetes can occur due to pancreatic infections, steroid use, alcohol, or chronic pancreatitis etc. Another form, known as NODAT (New Onset Diabetes After Transplant), has also been identified. Malnutrition-related diabetes (Type 5) arises when poor maternal nutrition during pregnancy prevents proper development of the child's pancreas, leading to early beta cell failure in adult life. A condition called “double diabetes” is also seen when children with Type 1 diabetes develop the features of Type 2 due to obesity. Diagnosis for Type 1DM often involves a C-peptide test, which measures how much insulin the body is still making. Importantly, early and strict sugar control provides lasting benefits, known as the Legacy Effect and Good Glycemic Memory, helping prevent complications of the kidney, heart, eyes, nerves, and other organs in subsequent years of life. Good glucose control also keeps mitochondria healthy, ensuring better long-term health. In addition, new GLP-1 analogs such as Tirzepatide and Semaglutide have shown benefits for weight reduction and organ protection, though they should only be taken under medical guidance. Expert- Dr Sunil Gupta Anchor- Mrs. Purva Kulkarni Podcast: 13/06/2025 Recorded at: Akashwani Nagpur Episode: 77

Testosterone replacement therapy (TRT) is becoming more common as more and more men suffer from low testosterone. But for many men, it might just treat the symptoms instead of the root cause: unhealthy body fat levels. In today's episode, we discuss a new study that compared one of the new weight loss drugs (tirzepatide) to TRT, to examine which is more effective for treating low testosterone. The results? Way beyond interesting! You're going to want to hear this. We also talk about other ways to increase your testosterone levels naturally. *** Do you like what you hear so far? Please leave a five-star review in your podcast player. And hit that follow button! You can also follow us on Instagram. You'll find Daniel at @strengthdan, and Philip at @philipwildenstam. Become a part of our Reddit community here. *** This podcast is brought to you by Styrkelabbet AB, Sweden. To support us, download the world's best gym workout tracker app StrengthLog here. It's completely ad-free and the most generous fitness app on the market, giving you access to unlimited workout logging, lots of workouts and training programs, and much, much more even if you stay a free user for life. If you want a t-shirt with ”Train hard, eat well, die anyway”, check out our shop here.

Welcome to The Peptide Podcast. In this episode, we're unpacking the latest on retatrutide and how it measures up against semaglutide and tirzepatide.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  https://pepties.com/partners/ We'll look closely at what the studies tell us so far — from overall weight loss to reductions in visceral fat and how much lean muscle mass is preserved. We'll also talk about where the evidence is solid, where it's still developing, and why cross-trial comparisons should be made with caution. What is retatrutide? So let's start with the basics—what is retatrutide? Retatrutide is a new type of weight-loss medication called a triple agonist. That sounds fancy, but what it really means is that it targets three hormone receptors in the gut and pancreas: GLP-1, GIP, and glucagon. Each of these plays a slightly different role in metabolism and appetite regulation. To break it down: GLP-1, which you might already know from drugs like semaglutide, mainly slows digestion, helps you feel full, and improves insulin sensitivity. GIP, which tirzepatide targets along with GLP-1, also helps regulate blood sugar and may improve how the body stores and burns fat. Retatrutide adds glucagon receptor activation on top of that, which seems to further boost fat burning. So how does this compare to semaglutide and tirzepatide? Semaglutide is a GLP-1-only drug, so it mainly works by reducing appetite and slowing gastric emptying. Tirzepatide is a dual agonist, hitting GLP-1 and GIP, which gives it a slightly stronger effect on blood sugar control and fat metabolism compared to semaglutide. Retatrutide goes one step further by adding glucagon activity, potentially giving more total fat loss. In other words, you can think of it like a spectrum: semaglutide hits one target, tirzepatide hits two, and retatrutide hits three—each additional receptor seems to enhance metabolic effects and fat loss in clinical trials. That's why people are excited about retatrutide, though it's still early, and we're waiting on larger studies to see exactly how it compares head-to-head with the others. And that's going to be key, since right now we don't have direct comparisons to other advanced therapies like semaglutide or tirzepatide in the published Phase 2 data. How does retatrutide compare to semaglutide and tirzepatide? Total body weight loss: Now let's put these three medications side by side and look at what the trials actually tell us about total body weight loss. Starting with retatrutide: in its Phase 2 obesity program, the numbers were unusually large, especially given the relatively short trial window. In the 48-week study, people on the higher doses—8 or 12 milligrams weekly—lost about 22 to 24% of their body weight on average. That's the result that really made headlines. It's worth noting that some trials report slightly different averages depending on the group studied—people with obesity but no diabetes versus people with type 2 diabetes—but across the board, that 48-week signal is consistently very strong. For comparison, let's step back to semaglutide at the 2.4 mg dose, which was tested in the pivotal STEP-1 trial. Over 68 weeks, participants lost about 15% of their body weight on average. That was a landmark finding when it was published in the New England Journal of Medicine—it essentially set the modern benchmark for what a GLP-1 monotherapy could do. Then we have tirzepatide, the dual GIP and GLP-1 agonist. The SURMOUNT-1 trial, which ran for 72 weeks, showed dose-dependent results: about 15% weight loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared to only around 3% with placebo. Other obesity studies with tirzepatide have backed this up, especially at the higher doses. And in head-to-head comparisons with semaglutide, tirzepatide has consistently come out on top. So if we zoom out: retatrutide's Phase 2 data suggest the greatest average reductions—over 22%—in less than a year. Tirzepatide follows closely behind with around 21% over 72 weeks. And semaglutide shows very meaningful, but smaller, weight loss of around 15% over a similar time frame. The big caveat here is that these aren't perfect apples-to-apples comparisons. The trials differed in their length, the types of patients enrolled—some had type 2 diabetes, some did not—their baseline weights, and even the way results were reported. Plus, retatrutide is still in Phase 2 for obesity, whereas semaglutide and tirzepatide already have large Phase 3 programs and real-world data backing them up. Visceral fat reduction: Next, let's talk about visceral fat reduction—that's the deep fat that surrounds organs like the liver, pancreas, and intestines. It's particularly important because high levels of visceral fat are strongly linked to cardiometabolic disease. Starting with retatrutide, one of the Phase 2 substudies used DEXA scans to measure body composition in detail. At the higher doses—8 and 12 milligrams per week—participants saw visceral fat drop by about 29 to 31% over 48 weeks. That's a very large relative reduction in under a year and one of the reasons people are excited about retatrutide's potential not just for weight loss, but also for improving long-term metabolic health. How does that compare to the other drugs? With semaglutide, we also have DEXA and imaging substudies from the STEP program and follow-up mechanistic work. These consistently show meaningful visceral fat reductions, along with improvements in the ratio of lean to fat mass. The difference is that semaglutide studies typically report VAT changes as “significant and clinically relevant,” but they don't always publish one clear headline number that's directly comparable to retatrutide's ~30%. In other words, semaglutide definitely lowers visceral fat, but depending on the study and population, the exact percentage looks different. For tirzepatide, we also have imaging-based data from the SURMOUNT trials and related body-composition studies. These show that the majority of weight lost is fat mass—including a significant portion of visceral fat. Some analyses report reductions on par with what's seen with GLP-1 therapies, while others suggest tirzepatide may push a bit further. But again, the actual percentages vary depending on whether the study used DEXA, CT, or MRI, and on who was enrolled. The big caveat here is that we don't yet have a head-to-head imaging study comparing all three drugs in the same population with the same methods. Retatrutide's ~30% visceral fat drop is certainly eye-catching, but without that kind of standardized comparison, it's hard to say definitively whether it's truly better than semaglutide or tirzepatide. Lean muscle mass preservation: Now let's shift to lean mass preservation, which is just as important as total weight or fat loss. Across all of the modern obesity drug trials, one thing has been consistent: most of the weight people lose is fat, but some lean tissue is lost too. That's expected whenever you're in a sustained calorie deficit. The question is how much muscle is preserved, and how the proportions break down. With retatrutide, the DEXA substudy showed something reassuring. Even though people lost a lot of total weight and fat, the proportion of lean mass lost compared to total weight loss was similar to what we see with other therapies. In other words, the drug seems to drive large fat reductions without causing disproportionate muscle loss. Interestingly, the absolute amount of lean tissue lost in kilograms was pretty stable across different doses, even though fat loss varied quite a bit. That suggests the extra weight loss with higher doses is really coming from fat, not muscle. Looking at semaglutide, the STEP trials with DEXA scans reported the same general pattern. People lost more fat than lean mass, and when you adjust for the total weight loss, body composition actually improved. In fact, some analyses showed a slight increase in the percentage of body weight that was lean tissue, even though the absolute lean mass in kilograms went down. So again, it's not that muscle isn't affected—it is—but fat loss makes up the majority of the change. For tirzepatide, the SURMOUNT body-composition studies found that about 75% of the weight lost is fat and about 25% is lean mass. That split is very similar to what was seen in the placebo groups, which means the drug isn't shifting the balance unfavorably. It preferentially reduces fat, while lean mass preservation is in the same ballpark as semaglutide and retatrutide. Now, here's the important nuance: lean mass on a DEXA scan isn't just skeletal muscle. It includes water, organ tissue, and other components. So if someone loses 3 or 4 kilograms of “lean mass,” we don't know how much of that is functional muscle versus water or smaller organ size. That's why these numbers can be misleading if you take them at face value. And this is where lifestyle comes in. Resistance training and adequate protein intake are critical alongside medication. Lifting weights or doing bodyweight resistance work helps preserve functional muscle, while getting enough protein—typically somewhere in the range of 0.8 to 1 gram per pound per day depending on age and activity—supports muscle repair and maintenance. Every trial we've seen shows that the best outcomes, in terms of maintaining strength and function, come from pairing these drugs with exercise and nutrition strategies. That way, the unavoidable lean mass changes have far less impact on long-term metabolic health and performance. Limitations, biases, and what's missing (the critical context). No large, peer-reviewed head-to-head trials (yet) comparing retatrutide with semaglutide or tirzepatide for the same endpoints using identical imaging protocols. Most comparisons are cross-trial and therefore imperfect. Retatrutide Phase-2 was often compared to placebo or dulaglutide (in the T2D DEXA substudy) rather than to semaglutide or tirzepatide. A head-to-head (planned/registered) study vs tirzepatide is listed on ClinicalTrials.gov but results are not published yet. Different populations & durations. Some retatrutide data come from cohorts that include people with T2D or NAFLD; semaglutide STEP trials were often in people with obesity (without diabetes) and run longer (68 weeks), while tirzepatide SURMOUNT trials ran to 72 weeks. These differences change the absolute and percent outcomes. Funding and reporting bias. Many of the early retatrutide analyses are industry-funded (Eli Lilly), which is standard for drug development, but it requires us to carefully read methods, endpoints, and completeness of reporting. Independent replication and Phase-3 confirmation matter. Imaging method variation. VAT reported by DXA vs MRI vs CT are not directly interchangeable. Some trials report VAT area, others percent change; that complicates cross-trial percent comparisons.  Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend. Until next time, be well, and as always, have a happy, healthy week.

https://linktr.ee/manonthemounjaro Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-451 Overview: The obesity epidemic has fueled a demand for weight loss medications. Trials have directly compared medications—specifically glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—with a recent study doing just that. Tune in as we explore the evidence comparing semaglutide and tirzepatide for weight loss outcomes up to 1 year. Episode resource links: Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064.  Moiz A, Filion KB, Toutounchi H, et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025;178(2):199-217.  Wen J, Syed B, Nadora D, et al. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies. Endocrinol Diabetes Metab. 2025;8(3):e70045.  Guest: Alan M. Ehrlich, MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

In this special episode on Obstructive Sleep Apnea our host, Dr. Neil Skolnik will discuss treatment of OSA. In Part 1 we discussed an overview of OSA, in Part 2 we discussed making the diagnosis, Part 3 was treatment, and in Part 4 we bring it all together with a case to explore clinical decision making for OSA. This special episode is supported by an independent educational grant from Lilly. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Dr. Sanjay Patel, M.D, Professor of Medicine, Epidemiology, & Clinical and Translational Science, and Director of the Center for Sleep and Cardiovascular Outcomes Research; Medical Director of the Comprehensive Sleep Disorders Program, University of Pittsburgh Medical Center Susan Kuchera, M.D. - Clinical Associate Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University and Program Director of the Family Medicine Residency at Jefferson Health Abington. Selected references: Diagnosis and Management of Obstructive Sleep Apnea - A Review. JAMA. 2020;323(14):1389-1400 Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193-1205  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-451 Overview: The obesity epidemic has fueled a demand for weight loss medications. Trials have directly compared medications—specifically glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—with a recent study doing just that. Tune in as we explore the evidence comparing semaglutide and tirzepatide for weight loss outcomes up to 1 year. Episode resource links: Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064.  Moiz A, Filion KB, Toutounchi H, et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025;178(2):199-217.  Wen J, Syed B, Nadora D, et al. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies. Endocrinol Diabetes Metab. 2025;8(3):e70045.  Guest: Alan M. Ehrlich, MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Step into the “Skinny Games” with Dr. Sofia Din, a board-certified longevity doctor in New York.

I'm leaving for my yearly Disney trip for the T1D conference, and y'all — nothing will humble you more than a three-way dressing-room mirror. I tried on one of those athletic dresses and BAM: back-fat in the mirror I'd never noticed before. Cue the body image vacation panic. But I refused to let bad lighting and spandex steal my trip. In this episode, I tell the whole embarrassing story, exactly how I knocked myself out of that spiral, and why you absolutely cannot put your life on hold until the scale says so.

Sick of trying fad diets that just don't seem to work for you? Find out how to simplify your approach and succeed by learning and applying the principles of weight management.  How to make calories work for you Which proteins are better than others and when to eat protein Preserving lean muscle while losing body fat "Dirty" vs "Clean" diets Including desert and candy during a weight loss journey   APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

AI accelerates drug discovery while steroids turn teens into aggressive strangers. Dr. Michael Israetel explores our pharmaceutical crossroads here!Full show notes and resources can be found here: jordanharbinger.com/1209What We Discuss with Michael Israetel:GLP-1 drugs like Tirzepatide offer massive health benefits beyond weight loss — reducing inflammation, improving brain health, and decreasing addiction behaviors, even for people already in good shape.Steroids don't just amplify personality — they specifically amplify masculine traits like aggression and reduce empathy. Starting young can permanently rewire your brain's emotional and social processing.AI is about to revolutionize medicine by testing millions of drug candidates virtually, creating treatments 10x more effective with 10x fewer side effects. We're entering the pharmaceutical iPhone moment.The "only take drugs when sick" mindset worked in the 20th century, but is becoming dangerously outdated — like refusing elevators because you prefer human operators.When your diet plateaus, take a week-long break eating at maintenance. Your stress hormones will drop, body water will flush out, and you'll often look leaner than before.And much more...And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors:Saily: 15% off: saily.com/jordanharbinger, code JORDANHARBINGERDripDrop: 20% off: DripDrop.com, code JORDANLinkedIn Jobs: Post your job for free: linkedin.com/jordanQuince: Free shipping & 365-day returns: quince.com/jordanBetterHelp: 10% off first month: betterhelp.com/jordanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Remote Screening for Asymptomatic Atrial Fibrillation Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock Helicobacter pylori Screening After Acute Myocardial Infarction Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis Participation of Women in Cardiovascular Trials From 2017 to 2023 Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Remote Screening for Asymptomatic Atrial Fibrillation Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock Helicobacter pylori Screening After Acute Myocardial Infarction Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis Participation of Women in Cardiovascular Trials From 2017 to 2023 Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

Welcome back to Ozempic Weightloss Unlocked, the show that brings listeners the most current news, research, and perspectives on Ozempic, the medication that has transformed weight loss conversations everywhere.Ozempic, generically known as semaglutide, was originally approved for type two diabetes by the FDA in 2017. Its follow-up, Wegovy, hit the market in 2021 explicitly for chronic weight management. Both drugs belong to a class called glucagon-like peptide-one receptor agonists. These medications work by mimicking a naturally occurring hormone that helps the body regulate blood sugar after meals while also reducing appetite by slowing the digestive process. Many patients taking Ozempic weekly have seen impressive reductions in body weight—up to 16 percent, according to data highlighted by the American Journal of Managed Care.The popularity of Ozempic exploded when its weight loss effects were amplified on social media and through celebrity endorsements. Demand surged, and global interest grew as more people sought medical solutions outside of diet and exercise alone. But Ozempic is not just hype—it's backed by multiple clinical trials and growing medical consensus, though not without debate.Researchers continue to push the boundaries, and major updates are underway. According to Fox News Digital and the Times of India, scientists at Tufts University have developed a next-generation experimental drug aimed at delivering weight loss of up to thirty percent—nearly matching surgical outcomes but without the operation. This new compound works across four hormone pathways: GLP-1, GIP, glucagon, and peptide YY, aiming to deliver robust weight loss with fewer side effects like nausea and muscle loss. The “quadruple-action” drug is still in early preclinical stages, tested only in cells—not yet in humans or animals—but represents a bold step towards more personalized, gentle, and sustainable weight management therapies.For now, single-hormone agents like Ozempic remain widely prescribed. Experts urge those on GLP-1 medications to partner closely with their clinicians, focusing on daily protein, hydration, and resistance training to mitigate risks such as muscle loss and malnutrition. Nutritional support is key, as well as regular follow-ups.Alongside medical progress, litigation and warnings continue to surface. The Lawsuit Information Center reports that thousands of claimants have entered into multidistrict litigation over Ozempic and similar drugs, citing side effects like gastroparesis, or stomach paralysis, and rare forms of vision loss including neovascular age-related macular degeneration and optic neuropathy. A 2025 study out of the University of Toronto found semaglutide users twice as likely to develop macular degeneration compared to others—a small risk, but real and statistically significant. Another concern comes from JAMA Otolaryngology–Head & Neck Surgery, showing a possible increased risk of thyroid cancer among GLP-1 agonist users. The defense argues that many of these side effects are rare, and some findings may be linked to increased medical surveillance, rather than the drug itself. Physicians and patients are encouraged to weigh these risks alongside the benefits and always discuss options thoroughly before starting treatment.As for what comes next, listeners should keep an eye on innovations underway: oral drugs like orforglipron, combination therapies such as CagriSema, and monthly injectables from major firms—all targeting more effective weight loss with easier dosing and fewer downsides. Tirzepatide, branded as Zepbound, is currently considered one of the most potent with trial data showing up to twenty-one percent body weight loss.The obesity epidemic is far from solved, but the next wave of treatments could make weight loss less about suffering and more about smart science. Whether listeners are considering Ozempic, awaiting newer options, or just tuning in for updates, the biggest takeaway is this: work with a trusted healthcare provider, stay informed about the latest findings, and balance medication with healthy lifestyle habits.Thank you for tuning in to Ozempic Weightloss Unlocked. Do not forget to subscribe and share. This has been a Quiet Please production—for more, check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

I'm back from my summer break, and today we're talking about what it really means to come out of survival mode and step into a new season of life. When you're just trying to make it through, the world feels blurry. You don't even notice the little things piling up around you. But once you start to shift, it's like everything comes back into focus: the appointments you've been putting off, the house that suddenly needs cleaning, and most importantly, you.In this episode, I'm sharing a summer recap (including an upcoming Disney trip I didn't think would happen), how back-to-school season has me reflecting on my own routines, and why fall is the perfect reminder that change can be beautiful.

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review:   1.     Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity  - NEJM   2.     Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3)– Lancet Diabetes Endocrinology    3.     Nutritional priorities to support GLP-1 therapy for Obesity – A Joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society - American Journal of Clinical Nutrition 4.     Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events – Diab Care 5.     Tirzepatide as Compared with Semaglutide for the Treatment of Obesity – NEJM For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Remote Screening for Asymptomatic Atrial Fibrillation Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock Helicobacter pylori Screening After Acute Myocardial Infarction Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis Participation of Women in Cardiovascular Trials From 2017 to 2023 Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

In this episode, Tina returns from a summer break to discuss her experience with microdosing GLP-1, particularly with the peptide Tirzepatide. She shares insights on GLP-1's misconceptions, its benefits for metabolism, and its impact on women in perimenopause and menopause. Emphasizing the importance of individualized medical advice, she shares details of her journey using peptides for her chronic condition, inflammatory issues, and appetite control. Additionally, she introduces her preferred telehealth provider and upcoming programs to support women considering peptide usage. Here's what you'll learn: - How my ulcerative colitis journey led me to try peptides - The mistakes I made buying and mixing peptides at home - The misconceptions I had about GLP-1s and what I learned instead - Why microdosing a GLP-1 might help with inflammation, blood sugar, and appetite - The surprising benefits for women in perimenopause and menopause - How my eating habits completely changed in just eight weeks - Why caffeine and alcohol suddenly aren't as appealing - My current peptide and supplement stack, and what I plan to keep long term - What's next for me and how you can learn more if you're curious Free Training: Hormone-Driven Fat Loss Method: https://carrotsncake.kit.com/5909f18b13 Peptides for Women course: https://carrotsncake.com/offers/3Q7wttmr?coupon_code=PROTOCOL19 Our trusted telehealth partner: https://elliemd.com/tinahaupert https://carrots-n-cake.mykajabi.com/fit+fueled Connect with Tina Haupert: https://carrotsncake.com/ Facebook: Carrots 'N' Cake https://www.facebook.com/carrotsncake Instagram: carrotsncake https://www.instagram.com/carrotsncake YouTube: Tina Haupert https://www.youtube.com/user/carrotsncake About Tina Haupert: Tina Haupert is the owner of Carrots ‘N' Cake as well as a Certified Nutrition Coach and Functional Diagnostic Nutrition Practitioner (FDN-P). Tina and her team use functional testing and a personalized approach to nutrition to help women find balance within their diets while achieving their body composition goals.

Peptides Vs. Steroids: The Safer Road to Building Muscle & Defeating Fat Amslifestylemedicine.com/ About the Guest(s): Dr. Maureen Gibbons, affectionately known as Dr. Mo, is an emergency medicine and obesity medicine board-certified physician turned lifestyle medicine entrepreneur. She is the founder of AMS Lifestyle Medicine, a practice dedicated to helping patients reclaim food freedom, improve metabolic health, and lead fulfilling lives. Dr. Mo is also an accomplished author, guiding individuals through transformative health journeys with works like her latest book, "Freedom to Shift: Lose the Weight and Gain Your Freedom." Episode Summary: In this enlightening episode of The Chris Voss Show, Dr. Mo graces the podcast to share her riveting journey from being an emergency medicine practitioner to a leading figure in lifestyle medicine. Host Chris Voss humorously opens the session, promising listeners an engaging and educative rollercoaster, with guests that are sure to leave listeners both informed and inspired. Dr. Mo delves deep into her personal struggles with weight and eating habits, revealing how her own experiences motivated her to pivot into the field of lifestyle medicine. Tackling a variety of topics, Dr. Mo elaborates on the physiological and habitual causes of weight struggles, highlighting the innovative solutions her practice offers. From cutting-edge medications like Tirzepatide, better known as Manjaro, to the significant impact of hormones on weight and health, Dr. Mo provides valuable insights into how her practice helps patients break free from their chains of food obsession. Through AMS Lifestyle Medicine, Dr. Mo and her team offer telehealth services, including weight management and TRT programs, empowering people to lead healthier, more balanced lives by providing personalized support and actionable strategies. Key Takeaways: Dr. Mo transitioned from a successful career in emergency medicine to focus on lifestyle medicine, inspired by her personal battles with food and weight. Her practice, AMS Lifestyle Medicine, uses innovative treatments like Tirzepatide and lifestyle coaching to help patients overcome metabolic and weight challenges. Hormonal imbalances are pivotal in weight management, and medications like Tirzepatide can effectively address these issues. Dr. Mo emphasizes the importance of understanding the psychological and habitual triggers of weight issues, offering a holistic approach to treatment. Telehealth services provided by AMS Lifestyle Medicine offer patients nationwide access to personalized care and innovative weight management solutions. Notable Quotes: "I knew that I had credentialed a couple years ago because I had someone in COVID, one of my good friends, replaced her income through telehealth." "Medication's a tool, you know, and that's the big thing in the media. Oh, it's a skinny shot. It's a magic pill. I wish." "For a lot of people, and like I said, semaglutide is a great drug for a lot of people, but for some it's just not." "I'm counting the collagen. Leave me alone." "If you're in there and you're like, yeah, I think you guys are crazy and I don't really like the way you do things. You don't pay."

Metformin for Treatment of Knee Osteoarthritis in Patients With Overweight or ObesityOnce-Weekly Semaglutide in Persons with Obesity and Knee OsteoarthritisSemaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe

In this episode of the RWS Clinician's Corner, Margaret Floyd Barry sits down with Dr. Tyna Moore—renowned naturopathic physician, chiropractor, and international speaker with almost 30 years of experience in holistic and regenerative medicine. Dr. Tyna is known for her bold approach to metabolic health, especially her unique use of GLP-1 agonists like semaglutide, not just for weight loss but as powerful tools for longevity, healing, and resilience. Dr. Tyna pulls back the curtain on the true clinical potential of these peptides, busting myths and exploring the nuance lost in today's clickbait headlines.   In this interview, we discuss:   The science behind GLP-1s and GLP-1 Agonists (including mechanism of action and effects) Microdosing/personalized dosing of GLP-1s, including clinical uses beyond weight loss The concept of “cycling” versus lifelong usage (compared to hormone therapy) Potential side effects and dosing management (including contraindications and safety) Compounded GLP-1s: access, regulations, and practicalities Industry resistance, misinformation, and social dynamics Using GLP-1s during gut healing protocols and the limits of natural alternatives The Clinician's Corner is brought to you by Restorative Wellness Solutions.  Follow us: https://www.instagram.com/restorativewellnesssolutions/    Connect with Dr. Tyna Moore: Website: http://www.drtyna.comInstagram: https://www.instagram.com/drtyna/ YouTube: https://www.youtube.com/@drtyna   Click here for Dr. Tyna's Free 4-part video Series, GLP-1 Uncovered. This video series concludes with an offer for her course, GLP-1s Done Right University. Enter coupon code MARGARET to receive a special discount: https://www.drtyna.com/ozempicuncovered   Or, to go directly to the course, GLP-1s Done Right University, click here and enter the same coupon code (MARGARET) to get started.  Timestamps: 00:00 Regenerative Medicine and Hormone Therapy  05:57 Functional Medicine Truth vs. Propaganda  14:17 Regenerative Therapy Requires Low Inflammation  16:08 Widespread Cardiometabolic Health Crisis  22:16 "Managing Health Challenges with Medication"  30:29 "Low-Dose Approach for Diabetes Management"  36:16 "Empowering Patients Through Education"  38:58 Custom Medication Dosing Benefits  44:43 503B Compounding Pharmacies Shutdown  52:51 Understanding Peptides in Modern Healthcare  57:15 Biliary Concerns in GLP-1 Use  59:14 Liver Health and Supplement Advice  01:06:57 Optimizing Gut Microbiome Strategies  01:10:17 "GLP-1 for Health Improvement" 01:15:29 "Rediscovering Physical Fitness" Speaker bio:    With nearly thirty years immersed in the medical field, Dr. Tyna Moore is an expert in holistic regenerative medicine and resilient metabolic health. She is licensed as a Naturopathic Physician and a Chiropractor, drawing on knowledge from both traditional and alternative fields of science and medicine to provide a comprehensive perspective to individuals striving to enhance their health and wellbeing. Dr. Tyna holds degrees from the National College of Natural Medicine, an esteemed naturopathic medical school, and the University of Western States Chiropractic College. Her work is not just about treating symptoms, it's about understanding and healing root causes to build a robust foundation for long term wellbeing. She is well known for her fierce and open-minded exploration of the peptide, Semaglutide/Ozempic, as a longevity tool for healing. Dr. Tyna champions medical autonomy and individual accountability, and she is on a mission to help as many people as possible experience the freedom and joy that health brings.   As the host of The Dr. Tyna Show Podcast, a top ranking podcast in the health and wellness space, and an international speaker, she is dedicated to empowering others to take control of their wellbeing, heal their metabolic health, and build strength and resilience. Her cornerstone recommendations for every patient and listener: weight lifting and sunshine. Additionally, she extends her expertise to support fellow doctors in cultivating their online practices, helping them transition away from the insurance-centric model to reclaim time, financial stability, and freedom.   Dr. Tyna lives in Oregon with her husband and daughter, and is a proud dog mama. Keywords: GLP-1 agonists, semaglutide, tirzepatide, peptides, regenerative medicine, metabolic health, weight loss strategies, microdosing, hormone replacement therapy, insulin resistance, appetite suppression, personalized dosing, compounding pharmacies, side effects, gut health, SIBO (small intestinal bacterial overgrowth), slow motility, inflammation, functional medicine, neuroregeneration, autoimmune conditions, BPC-157, muscle mass, pharmaceutical dosing, diabetes management, cardiovascular health, leaky gut, obesity, perimenopause, patient empowerment, cycling peptides   Disclaimer: The views expressed in the RWS Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of Restorative Wellness Solutions, LLC. Restorative Wellness Solutions, LLC does not specifically endorse or approve of any of the information or opinions expressed in the RWS Clinician's Corner series. The information and opinions expressed in the RWS Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. Restorative Wellness Solutions, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the RWS Clinician's Corner series. By viewing or listening to this information, you agree to hold Restorative Wellness Solutions, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

From diabetes care to weight loss trends, GLP-1 agonists are everywhere. In this episode, we unpack the science, social media hype, ethical dilemmas, and side effects surrounding Ozempic, Wegovy, and more. Featuring Dr. Jodie Gee, a Clinical Assistant Professor here at University of Houston College of Pharmacy, and a Ambulatory Care Clinical Pharmacists at Vecino's Denver Harbor Family Clinic, we explore her insights on the role of GLP-1As in patient care. Stay at the end for an in-depth highlight of the newly FDA-approved tirzepatide!

Jessica Brennan, started in the fitness industry 10 years ago as a fitness instructor and personal trainer, realized early on that achieving health goals went beyond physical activity. This realization led Jessica to pursue certifications in nutrition, hormone specialist, and gut health specialist, aiming to address health challenges holistically. Working closely with Karen at Hormone Solutions, Jessica is dedicated to sharing her expertise with women globally. Her areas of expertise include bodybuilding, women's hormone health, personalized nutrition, peptide therapy, and chronic illness management. Jessica is with me this time to discuss our one-year anniversary of being on weight loss peptides. We also created our weight loss peptide group about a year ago which, in addition to our own experiences, has provided us many different points of view on the ups and downs that members face. We'll share personal stories and lessons learned from our community of over 200 members, discussing the use of GLP-1 peptides, strategies for minimizing side effects, and the importance of muscle preservation. We also get into how peptides can improve sleep, athletic performance, and hormonal balance. In this episode: How weight loss peptides and hormone optimization can transform wellness and fitness goals. Optimizing peptide regimens to minimize side effects and prevent muscle loss. Why holistic health approaches are crucial for long-term wellness beyond just weight reduction. Why addressing foundational health practices enhances the success of hormonal treatments. How hormone balance plays a crucial role in weight control and muscle preservation, especially during menopause. Why effort and the right mindset are non-negotiables for achieving fitness goals. How the CAROL Bike can aid in maximizing workout efficiency while using peptides. Why women should progress beyond comfort zones in weightlifting for muscle development. How peptides synergize with training, emphasizing workout efficiency for busy individuals. Why long-term peptide use may be necessary for ongoing health maintenance and weight management. How guilt associated with medication for weight control should be reframed as a preventive health measure. How GLP-1 agonists impact the immune system, mental health, and metabolic functions. Tirzepatide's positive influence on thyroid function. How addressing hormonal imbalances in conjunction with weight loss efforts leads to better outcomes. Why community support can be transformative in the health and fitness journey.   Sponsors Coupon KM20 to get 20% off your order of Vitali Skin Care! Get 40% off your Cozy Earth Bed Sheet with coupon code HORMONES     Are you in peri or post menopause and looking to optimize your hormones and health? At Hormone Solutions, we offer telemedicine services and can prescribe in every U.S. state, as well as in British Columbia, Alberta, and Ontario in Canada.   Visit karenmartel.com to explore our comprehensive programs: Bioidentical Hormone Replacement Therapy Individualized Weight Loss Programs  Peptide Therapy for weight loss    Interested in our NEW Peptide Weight Loss Program? Join today and get all the details here.   Join our Women's Peri and Post Menopause Group Coaching Program, OnTrack, TODAY!   To our nursing audience members, our podcasts qualify for nursing CE @ RNegade.pro. Provide # CEP17654.   Your host: Karen Martel Certified Hormone Specialist, Transformational Nutrition Coach, & Weight Loss Expert   Karen's Facebook Karen's Instagram

TakeawaysThe podcast features Dr. Grant Tinsley, a body composition expert.The discussion revolves around a case series on body composition effects.GLP-1 receptor agonists are a focus of the research.The importance of resistance training in weight loss is emphasized.Patient case studies provide insights into individual experiences.The first patient lost a significant amount of fat mass while preserving lean mass.The second patient achieved remarkable body composition changes in a short time.The third patient showed positive changes over a longer duration.The need for more randomized trials is highlighted.The conversation underscores the role of exercise and nutrition in weight management.Tap or Click here to see more from Dr. GrantTap here for scientific references in this episode.

Dr. Gillett and James O'Hara discuss a new study on TizepatideFor High-quality labs:► http://sagebio.com/For information on the Gillett Health clinic, lab panels, and health coaching:► https://GillettHealth.comFollow Gillett Health for more content from James and Kyle► https://instagram.com/gilletthealth► https://www.tiktok.com/@gilletthealth► https://twitter.com/gilletthealth► https://www.facebook.com/gilletthealthFollow Kyle Gillett, MD► https://instagram.com/kylegillettmdFollow James O'Hara, NP► https://Instagram.com/jamesoharanpFor 10% off Gorilla Mind products including SIGMA: Use code “GH10”► https://gorillamind.com/For discounts on high-quality supplements►https://www.thorne.com/u/GillettHealth#weightloss #trt #health #glp1 #testosteroneAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

In this special episode on Obstructive Sleep Apnea our host, Dr. Neil Skolnik will discuss treatment of OSA. In Part 1 we discussed and overview of OSA, in Part 2 we discussed making the diagnosis will, and Part 4 will look at cases. This special episode is supported by an independent educational grant from Lilly. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Dr. Sanjay Patel, M.D, Professor of Medicine, Epidemiology, & Clinical and Translational Science, and Director of the Center for Sleep and Cardiovascular Outcomes Research; Medical Director of the Comprehensive Sleep Disorders Program, University of Pittsburgh Medical Center Selected references: Diagnosis and Management of Obstructive Sleep Apnea - A Review. JAMA. 2020;323(14):1389-1400 Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193-1205

Why does joy feel so scary? Why do we hold back when life is good, waiting for something bad to happen? In this episode, I'm sharing why joy is the most vulnerable emotion we can feel and how that fear keeps us from fully living. We'll talk about why our brains default to “what if it all goes wrong,” how this ties into body image and weight loss, and why you don't need a smaller body to feel joy right now.I'm also giving you a personal update from my birthday and what's making me grateful (and a little nervous!) in this season of life. If you've ever struggled to let yourself be happy without guilt or fear, this one's for you.What you'll learn in this episode: ✔ Why joy is the most vulnerable emotion ✔ How fear of losing happiness sabotages your peace ✔ The connection between body image, weight loss, and joy ✔ Practical tips to embrace joy without waiting for the “perfect” moment

Dr. Centor discusses outcomes in patients with inadequately controlled type 2 diabetes when the dulaglutide dose is escalated versus switching to tirzepatide.

In first-ever study, keto diet scores vs. Parkinson's; Walk away from dementia; Loneliness can kill, but negative social ties can hasten biological aging; Researchers isolate potent memory compound from sage, rosemary; Sketchy knockoff weight loss drugs are flooding the marketplace; The popular vitamin you shouldn't take for sarcoidosis; When osteoporosis is so severe that even minor trauma causes rib fractures.

The VENTOUX study of endurance athletes, the 10,000 step myth was not busted, rate vs rhythm control for AF, and GLP1 drugs and observational studies are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Endurance Athletes and Arrhythmia (again) VENTOUX trial https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.125.018470 II Daily Step Count and Health — no myths were busted. Lancet Public Health: https://doi.org/10.1016/S2468-2667(25)00164-1 III Rate vs Rhythm Control of AF Medscape: Everyone Deserves a Shot at the American Dream: Sinus Rhythm https://www.medscape.com/viewarticle/everyone-deserves-shot-american-dream-sinus-rhythm-2025a1000jle This Week in Cardiology, July 11, 2025 https://www.medscape.com/viewarticle/1002704 AFFIRM trial https://www.nejm.org/doi/full/10.1056/NEJMoa021328 AFFIRM substudy https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/486560 IV GLP-1 Drugs and Observational Studies Neurodegeneration and Stroke After Semaglutide and Tirzepatide https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2836412 SUSTAIN-6 https://www.nejm.org/doi/full/10.1056/NEJMoa1607141 SELECT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

How the STEP-UP trial came to life,  and what made the 7.2mg dose possibleWhat the data actually says about weight loss and side effects at higher dosesWhy trial design, pharmacokinetics, and estimands matter more than you thinkWhat's coming next in obesity meds: duals, triples, and even antagonistsThe real talk on intermittent fasting, access issues, and preaching vs. scienceSign up for Dr. Spencer''s Clinic